Helicobacter Pylori
Rifampicin-based salvage therapy not suitable for H. pylori eradication
Published in Blood Weekly, June 23rd, 2005
"In vitro activity of rifampicin has been shown against Helicobacter pylori. It has also been reported that the prevalence of H. pylori is low in patients with tuberculosis treated with rifampicin.
"Clinical trials are required to establish the efficacy of rifampicin as a salvage therapy for eradication of H. pylori. We aimed to evaluate the efficacy of rifampicin-based salvage therapy for eradication of H. pylori in patients with peptic ulcer disease," investigators in India report.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2005-06-23)
More Articles from Blood Weekly
- Acute Myeloid Leukemia
Wnt/beta-catenin pathway involved in acute myeloid leukemia pathogenesis - Stem Cell Research
BM osteo-SCs stimulated with prostaglandin E-2 to treat segmental bone defect - Stem Cell Transplantation
Physician involvement in patient care associated with favorable HSCT outcomes - Tissue Engineering
Arthroscopically injectable vehicle developed for cell-assisted cartilage repair - Tissue Engineering
Hyaluronan- and polyester-based scaffolds used to repair osteochondral defects - Adverse Drug Reaction
Cyclosporine-related nephrotoxicity after renal transplantation is donor driven - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
